208 related articles for article (PubMed ID: 25362997)
21. Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse.
Ohsawa M; Mizoguchi H; Narita M; Chu M; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2000 Sep; 294(3):1106-11. PubMed ID: 10945866
[TBL] [Abstract][Full Text] [Related]
22. Spinal cord stimulation modulates supraspinal centers of the descending antinociceptive system in rats with unilateral spinal nerve injury.
Tazawa T; Kamiya Y; Kobayashi A; Saeki K; Takiguchi M; Nakahashi Y; Shinbori H; Funakoshi K; Goto T
Mol Pain; 2015 Jun; 11():36. PubMed ID: 26104415
[TBL] [Abstract][Full Text] [Related]
23. The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: correlation of nociceptive behavior and c-fos expression.
Gogas KR; Presley RW; Levine JD; Basbaum AI
Neuroscience; 1991; 42(3):617-28. PubMed ID: 1659673
[TBL] [Abstract][Full Text] [Related]
24. Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice.
Nakamoto K; Aizawa F; Miyagi K; Yamashita T; Mankura M; Koyama Y; Kasuya F; Hirasawa A; Kurihara T; Miyata A; Tokuyama S
PLoS One; 2017; 12(7):e0180610. PubMed ID: 28723961
[TBL] [Abstract][Full Text] [Related]
25. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
[TBL] [Abstract][Full Text] [Related]
26. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.
Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E668-76. PubMed ID: 23341496
[TBL] [Abstract][Full Text] [Related]
27. GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model.
Khan MZ; Zhuang X; He L
Neurobiol Learn Mem; 2016 May; 131():46-55. PubMed ID: 26976092
[TBL] [Abstract][Full Text] [Related]
28. A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation.
Fujita T; Matsuoka T; Honda T; Kabashima K; Hirata T; Narumiya S
J Invest Dermatol; 2011 Aug; 131(8):1660-7. PubMed ID: 21593768
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
[TBL] [Abstract][Full Text] [Related]
30. Antinociceptive profiles and mechanisms of centrally administered oxyntomodulin in various mouse pain models.
Park SH; Lee JR; Jang SP; Park SH; Lee HJ; Hong JW; Suh HW
Neuropeptides; 2018 Apr; 68():7-14. PubMed ID: 29366515
[TBL] [Abstract][Full Text] [Related]
31. Agonism of Gpr40 Protects the Capacities of Epidermal Stem Cells (ESCs) Against Ultraviolet-B (UV-B).
Sun C; Li Y; Li X; Sun J
Drug Des Devel Ther; 2020; 14():5143-5153. PubMed ID: 33262575
[TBL] [Abstract][Full Text] [Related]
32. [The role of brain n-3 fatty acids-GPR40/FFAR1 signaling in pain].
Nakamoto K; Tokuyama S
Nihon Yakurigaku Zasshi; 2018; 151(1):21-26. PubMed ID: 29321392
[TBL] [Abstract][Full Text] [Related]
33. The role of polyunsaturated fatty acids and GPR40 receptor in brain.
Khan MZ; He L
Neuropharmacology; 2017 Feb; 113(Pt B):639-651. PubMed ID: 26005184
[TBL] [Abstract][Full Text] [Related]
34. Agonists and protein kinase C-activation induce phosphorylation and internalization of FFA1 receptors.
Sosa-Alvarado C; Hernández-Méndez A; Romero-Ávila MT; Sánchez-Reyes OB; Takei Y; Tsujimoto G; Hirasawa A; García-Sáinz JA
Eur J Pharmacol; 2015 Dec; 768():108-15. PubMed ID: 26526350
[TBL] [Abstract][Full Text] [Related]
35. Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists.
Liu C; Li Z; Shi W; Li H; Wang N; Dai Y; Liao C; Huang W; Qian H
Chem Biol Drug Des; 2018 Aug; 92(2):1547-1554. PubMed ID: 29777569
[TBL] [Abstract][Full Text] [Related]
36. Taltirelin, a thyrotropin-releasing hormone analog, alleviates mechanical allodynia through activation of descending monoaminergic neurons in persistent inflammatory pain.
Eto K; Kim SK; Nabekura J; Ishibashi H
Brain Res; 2011 Sep; 1414():50-7. PubMed ID: 21872219
[TBL] [Abstract][Full Text] [Related]
37. Involvement of Descending Serotonergic and Noradrenergic Systems and their Spinal Receptor Subtypes in the Antinociceptive Effect of Dipyrone.
Gencer A; Gunduz O; Ulugol A
Drug Res (Stuttg); 2015 Dec; 65(12):645-9. PubMed ID: 25647230
[TBL] [Abstract][Full Text] [Related]
38. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC
Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671
[TBL] [Abstract][Full Text] [Related]
39. Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System.
Hiroki T; Suto T; Saito S; Obata H
Anesth Analg; 2017 Oct; 125(4):1281-1288. PubMed ID: 28787345
[TBL] [Abstract][Full Text] [Related]
40. Possible antinociceptive mechanisms of opioid receptor antagonists in the mouse formalin test.
Choi SS; Han KJ; Lee HK; Han EJ; Suh HW
Pharmacol Biochem Behav; 2003 May; 75(2):447-57. PubMed ID: 12873637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
